Adults with cancer enter clinical trials at a dismal rate of 3 percent or less, with even lower participation among minority populations.  To improve this absurdly low number it is time that we look at this life-and-death decision from a patient’s perspective, a viewpoint that is rarely considered in trial design.

Cancer patients know they have a potentially terminal illness, have often failed first and second therapies, and are desperate for better treatment of their disease.  Why wouldn’t they be …